| Website | cyterix.com |
| Category | BioTech |
| Phone | (415) 865-2059 |
| info@cyterix.com | |
| Employees |
| TOTAL | $9.2M |
| FUNDING TOTAL | $9.2M |
| Series A, 6/11 The Column Group SV Life Sciences | $9.2M |
Cyterix Pharmaceuticals, Inc., a privately held cancer therapeutics company, is engaged in the discovery and development of new classes of small molecule prodrugs with improved safety and efficacy over traditional drugs. The company’s approach, based on a proprietary technology platform, uniquely enables the design of multiple classes of anticancer prodrugs that are selectively activated by extra-hepatic cytochrome P450 enzymes that are greatly over-expressed in a broad range of solid tumor and hematologic cancers, but not in normal tissues.
